Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
PLoS One ; 17(6): e0269241, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35657782

RESUMEN

INTRODUCTION: Obesity is a common disease and a known risk factor for many other conditions such as hypertension, type 2 diabetes, and cancer. Treatment options for obesity include lifestyle changes, pharmacotherapy, and surgical interventions such as bariatric surgery. In this study, we examine the use of prescription drugs and dietary supplements by the individuals with obesity. METHODS: We conducted a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2003-2018. We used multivariate logistic regression to analyze the correlations of demographics and obesity status with the use of prescription drugs and dietary supplement use. We also built machine learning models to classify prescription drug and dietary supplement use using demographic data and obesity status. RESULTS: Individuals with obesity are more likely to take cardiovascular agents (OR = 2.095, 95% CI 1.989-2.207) and metabolic agents (OR = 1.658, 95% CI 1.573-1.748) than individuals without obesity. Gender, age, race, poverty income ratio, and insurance status are significantly correlated with dietary supplement use. The best performing model for classifying prescription drug use had the accuracy of 74.3% and the AUROC of 0.82. The best performing model for classifying dietary supplement use had the accuracy of 65.3% and the AUROC of 0.71. CONCLUSIONS: This study can inform clinical practice and patient education of the use of prescription drugs and dietary supplements and their correlation with obesity.


Asunto(s)
Diabetes Mellitus Tipo 2 , Medicamentos bajo Prescripción , Estudios Transversales , Suplementos Dietéticos , Humanos , Encuestas Nutricionales , Obesidad/epidemiología , Medicamentos bajo Prescripción/uso terapéutico
2.
J Am Med Inform Assoc ; 27(10): 1547-1555, 2020 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-32940692

RESUMEN

OBJECTIVE: We sought to assess the need for additional coverage of dietary supplements (DS) in the Unified Medical Language System (UMLS) by investigating (1) the overlap between the integrated DIetary Supplements Knowledge base (iDISK) DS ingredient terminology and the UMLS and (2) the coverage of iDISK and the UMLS over DS mentions in the biomedical literature. MATERIALS AND METHODS: We estimated the overlap between iDISK and the UMLS by mapping iDISK to the UMLS using exact and normalized strings. The coverage of iDISK and the UMLS over DS mentions in the biomedical literature was evaluated via a DS named-entity recognition (NER) task within PubMed abstracts. RESULTS: The coverage analysis revealed that only 30% of iDISK terms can be matched to the UMLS, although these cover over 99% of iDISK concepts. A manual review revealed that a majority of the unmatched terms represented new synonyms, rather than lexical variants. For NER, iDISK nearly doubles the precision and achieves a higher F1 score than the UMLS, while maintaining a competitive recall. DISCUSSION: While iDISK has significant concept overlap with the UMLS, it contains many novel synonyms. Furthermore, almost 3000 of these overlapping UMLS concepts are missing a DS designation, which could be provided by iDISK. The NER experiments show that the specialization of iDISK is useful for identifying DS mentions. CONCLUSIONS: Our results show that the DS representation in the UMLS could be enriched by adding DS designations to many concepts and by adding new synonyms.


Asunto(s)
Suplementos Dietéticos , Bases del Conocimiento , Terminología como Asunto , Unified Medical Language System , Procesamiento de Lenguaje Natural
3.
Vasc Med ; 25(6): 549-556, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-32716254

RESUMEN

Little is known about the impact of oral anticoagulation (OAC) choice on healthcare encounters during venous thromboembolism (VTE) primary treatment. Among anticoagulant-naïve patients with VTE, we tested the hypotheses that healthcare utilization would be lower among users of direct OACs (DOACs; rivaroxaban or apixaban) than among users of warfarin. MarketScan databases for years 2016 and 2017 were used; healthcare utilization was identified in the first 6 months after initial VTE diagnoses. The 23,864 patients with VTE had on average 0.2 ± 0.5 hospitalizations, spent 1.3 ± 5.2 days in the hospital, had 5.7 ± 5.1 outpatient encounters, and visited an emergency department 0.4 ± 1.1 times. As compared to warfarin, rivaroxaban and apixaban were associated with fewer hospitalizations, days hospitalized, outpatient office visits, and emergency department visits after accounting for age, sex, comorbidities, and medications. Hospitalization rates were 24% lower (incidence rate ratio (IRR): 0.76; 95% CI: 0.69, 0.83) with rivaroxaban and 22% lower (IRR: 0.78; 95% CI: 0.71, 0.87) with apixaban, as compared to warfarin (IRR: 1.00 (reference)). Healthcare utilization was similar between apixaban and rivaroxaban users. Patients with VTE prescribed rivaroxaban and apixaban had lower healthcare utilization than those prescribed warfarin, while there was no difference when comparing apixaban to rivaroxaban. These findings complement existing literature supporting the use of DOACs over warfarin.


Asunto(s)
Anticoagulantes/administración & dosificación , Inhibidores del Factor Xa/administración & dosificación , Recursos en Salud/tendencias , Pirazoles/administración & dosificación , Piridonas/administración & dosificación , Rivaroxabán/administración & dosificación , Tromboembolia Venosa/tratamiento farmacológico , Warfarina/administración & dosificación , Administración Oral , Adulto , Anciano , Atención Ambulatoria/tendencias , Anticoagulantes/efectos adversos , Bases de Datos Factuales , Servicio de Urgencia en Hospital/tendencias , Inhibidores del Factor Xa/efectos adversos , Femenino , Hospitalización/tendencias , Humanos , Masculino , Persona de Mediana Edad , Visita a Consultorio Médico/tendencias , Pirazoles/efectos adversos , Piridonas/efectos adversos , Rivaroxabán/efectos adversos , Factores de Tiempo , Resultado del Tratamiento , Estados Unidos/epidemiología , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/epidemiología , Warfarina/efectos adversos
4.
J Am Med Inform Assoc ; 27(4): 539-548, 2020 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-32068839

RESUMEN

OBJECTIVE: To build a knowledge base of dietary supplement (DS) information, called the integrated DIetary Supplement Knowledge base (iDISK), which integrates and standardizes DS-related information from 4 existing resources. MATERIALS AND METHODS: iDISK was built through an iterative process comprising 3 phases: 1) establishment of the content scope, 2) development of the data model, and 3) integration of existing resources. Four well-regarded DS resources were integrated into iDISK: The Natural Medicines Comprehensive Database, the "About Herbs" page on the Memorial Sloan Kettering Cancer Center website, the Dietary Supplement Label Database, and the Natural Health Products Database. We evaluated the iDISK build process by manually checking that the data elements associated with 50 randomly selected ingredients were correctly extracted and integrated from their respective sources. RESULTS: iDISK encompasses a terminology of 4208 DS ingredient concepts, which are linked via 6 relationship types to 495 drugs, 776 diseases, 985 symptoms, 605 therapeutic classes, 17 system organ classes, and 137 568 DS products. iDISK also contains 7 concept attribute types and 3 relationship attribute types. Evaluation of the data extraction and integration process showed average errors of 0.3%, 2.6%, and 0.4% for concepts, relationships and attributes, respectively. CONCLUSION: We developed iDISK, a publicly available standardized DS knowledge base that can facilitate more efficient and meaningful dissemination of DS knowledge.


Asunto(s)
Suplementos Dietéticos , Bases del Conocimiento , Vocabulario Controlado , Bases de Datos Factuales , Humanos , Etiquetado de Productos , RxNorm , Unified Medical Language System
5.
Thromb Haemost ; 118(9): 1637-1645, 2018 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-30103250

RESUMEN

Oral anticoagulants used for the primary treatment of venous thromboembolism (VTE) include warfarin and the more recently introduced direct oral anticoagulants (DOACs), including rivaroxaban, apixaban, dabigatran and edoxaban. Information on the comparative safety of these medications in routine clinical practice is lacking. We identified patients with diagnoses for VTE and prescriptions for oral anticoagulants using claims data from a large U.S. insurance database from 2012 to 2017. Marginal structural logistic models were used to examine associations between type of oral anticoagulant and risk of all-cause mortality. Of 62,431 enrolees in this analysis, 51% were female and the mean age was 61.9 years. Initial oral anticoagulant prescriptions were for warfarin (n = 35,704), rivaroxaban (n = 21,064) and apixaban (n = 5,663). A total of 1,791 deaths occurred within 6 months of the initial oral anticoagulant prescription. Risk of all-cause mortality was not associated with having a prescription for warfarin versus any DOAC or between any head-to-head DOAC comparisons. Also, associations generally did not vary when stratified by VTE type, sex, age, co-morbidities (including renal disease) or anti-platelet medication use. In this observational study, the associations with all-cause mortality comparing DOACs versus warfarin agree with results from previous clinical trials and observational studies, while the associations for head-to-head DOAC comparisons provide new information on the comparative safety of DOACs. Our findings suggest that other criteria such as patient preference, cost, recurrent VTE risk or bleeding risk should be used when determining the choice of anticoagulant for the primary treatment of VTE.


Asunto(s)
Anticoagulantes/uso terapéutico , Tromboembolia Venosa/tratamiento farmacológico , Warfarina/uso terapéutico , Administración Oral , Anciano , Anciano de 80 o más Años , Dabigatrán/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pirazoles/uso terapéutico , Piridinas/uso terapéutico , Piridonas/uso terapéutico , Estudios Retrospectivos , Riesgo , Rivaroxabán/uso terapéutico , Análisis de Supervivencia , Tiazoles/uso terapéutico , Tromboembolia Venosa/epidemiología , Tromboembolia Venosa/mortalidad
6.
Stud Health Technol Inform ; 245: 370-374, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29295118

RESUMEN

Drug and supplement interactions (DSIs) have drawn widespread attention due to their potential to affect therapeutic response and adverse event risk. Electronic health records provide a valuable source where the signals of DSIs can be identified and characterized. We detected signals of interactions between warfarin and seven dietary supplements, viz., alfalfa, garlic, ginger, ginkgo, ginseng, St. John's Wort, and Vitamin E by analyzing structured clinical data and unstructured clinical notes from the University of Minnesota Clinical Data Repository. A machine learning-based natural language processing module was further developed to classify supplement use status and applied to filter out irrelevant clinical notes. Cox proportional hazards models were fitted, controlling for a set of confounding factors: age, gender, and Charlson Index of Comorbidity. There was a statistically significant association of warfarin concurrently used with supplements which can potentially increase the risk of adverse events, such as gastrointestinal bleeding.


Asunto(s)
Suplementos Dietéticos , Registros Electrónicos de Salud , Interacciones de Hierba-Droga , Warfarina/farmacología , Interacciones Farmacológicas , Ginkgo biloba , Humanos
7.
Stud Health Technol Inform ; 245: 614-618, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29295169

RESUMEN

The adverse events of the dietary supplements should be subject to scrutiny due to their growing clinical application and consumption among U.S. adults. An effective method for mining and grouping the adverse events of the dietary supplements is to evaluate product labeling for the rapidly increasing number of new products available in the market. In this study, the adverse events information was extracted from the product labels stored in the Dietary Supplement Label Data-base (DSLD) and analyzed by topic modeling techniques, specifically Latent Dirichlet Allocation (LDA). Among the 50 topics generated by LDA, eight topics were manually evaluated, with topic relatedness ranging from 58.8% to 100% on the product level, and 57.1% to 100% on the ingredient level. Five out of these eight topics were coherent groupings of the dietary supplements based on their adverse events. The results demonstrated that LDA is able to group supplements with similar adverse events based on the dietary supplement labels. Such information can be potentially used by consumers to more safely use dietary supplements.


Asunto(s)
Suplementos Dietéticos , Etiquetado de Medicamentos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Minería de Datos , Bases de Datos Factuales , Humanos , Etiquetado de Productos
8.
AMIA Annu Symp Proc ; 2016: 2053-2061, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-28269965

RESUMEN

As the clinical application and consumption of dietary supplements has grown, their side effects and possible interactions with prescribed medications has become a serious issue. Information extraction of dietary supplement related information is a critical need to support dietary supplement research. However, there currently is not an existing terminology for dietary supplements, placing a barrier for informatics research in this field. The terms related to dietary supplement ingredients should be collected and normalized before a terminology can be established to facilitate convenient search on safety information and control possible adverse effects of dietary supplements. In this study, the Dietary Supplement Label Database (DSLD) was chosen as the data source from which the ingredient information was extracted and normalized. The distribution based on the product type and the ingredient type of the dietary supplements were analyzed. The ingredient terms were then mapped to the existing terminologies, including UMLS, RxNorm and NDF-RT by using MetaMap and RxMix. The large gap between existing terminologies and ingredients were found: only 14.67%, 19.65%, and 12.88% of ingredient terms were covered by UMLS, RxNorm and NDF-RT, respectively.


Asunto(s)
Suplementos Dietéticos , Etiquetado de Productos , Vocabulario Controlado , Bases de Datos Factuales , Suplementos Dietéticos/normas , Etiquetado de Medicamentos , RxNorm , Unified Medical Language System
9.
AMIA Annu Symp Proc ; 2015: 1361-70, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26958277

RESUMEN

Herbal and dietary supplement consumption has rapidly expanded in recent years. Due to pharmacological and metabolic characteristics of some supplements, they can interact with prescription medications, potentially leading to clinically important and potentially preventable adverse reactions. Electronic health record (EHR) system provides a valuable source from which drug-supplement interactions can be mined and assessed for their clinical effects. A fundamental prerequisite is a functional understanding of supplement documentation in EHR and associated supplement coverage in major online databases. To address this, clinical notes and corresponding medication lists from an integrated healthcare system were extracted and compared with online databases. Overall, about 40% of listed medications are supplements, most of which are included in medication lists as nutritional or miscellaneous products. Gaps were found between supplement and standard medication terminologies, creating documentation difficulties in fully achieving robust supplement documentation in EHR systems. In addition, in the clinical notes we identified supplements which were not mentioned in the medication lists.


Asunto(s)
Suplementos Dietéticos , Interacciones Farmacológicas , Registros Electrónicos de Salud , Terminología como Asunto , Bases de Datos Factuales , Humanos , Medicamentos bajo Prescripción
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA